Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2026.03.09

High-Throughput Experimentation platform goes live in Hyderabad

The High Throughput Experimentation (HTE) platform is now operational at our Integrated R&D Campus in Hyderabad, India. The system integrates automated experimental execution with structured data capture to support reproducible, high-quality screening and full traceability of results.

Designed to evaluate multiple variables within a single experimental matrix, the platform enables rapid assessment of chemical space during route scouting, optimization, and troubleshooting activities. This supports data-driven route selection and reduces uncertainty prior to scale-up.

Reactions are conducted at microscale, minimizing material consumption while enabling broad condition screening. The capability extends beyond catalytic chemistry and includes diverse reaction classes such as biocatalysis, with further expansion planned.

HTE is particularly effective for screening categorical variables and selecting reagents in a structured and data-driven manner. Screening outputs are generated with downstream process development in mind, ensuring translation into scalable workflows rather than remaining isolated exploratory data.

The platform is intended to accelerate decision-making, improve experimental consistency, and enhance confidence in process development strategies across programs.

Share article

More News

2026.05.16

Sai Life Sciences grows topline by 29% & doubles net profit in FY26

EBITDA up by 56%YoY; Net Profit up by 109%YoY Hyderabad, May 14, 2026: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India’s fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the fourth quarter and full year ended 31 March 2026. Commenting on the performance during the […]
Read more

2026.05.11

Sai Life Sciences becomes first Indian CRDMO with a site powered by 100% renewable energy

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs), today announced that its Bidar campus — comprising Unit IV, the company’s flagship API manufacturing facility, and Unit VI, its animal health API manufacturing facility — now operates entirely on renewable power. With this […]
Read more

2026.04.06

Sai Life Sciences recognized as Best Organization for Women (BOW) 2026 by ET Edge

Sai Life Sciences has been recognized as a Best Organization for Women (BOW) 2026 by ET Edge, reinforcing its continued commitment to fostering an inclusive, supportive, and empowering workplace for women. This recognition reflects the organization’s sustained efforts to build an environment where women can thrive—both professionally and personally. At Sai, these efforts are anchored […]
Read more

2026.03.27

Inside Sai Life Sciences’ Integrated R&D Campus: Accelerating Drug Development

In a recent feature published in R&D World, Sai Life Sciences’ Integrated R&D Campus in Hyderabad is showcased as a model for accelerating drug discovery and development through true scientific integration.In the article, Dr. B.V.N.B.S. Sarma, Senior Vice President – Discovery, highlights how co-locating multidisciplinary teams—from medicinal chemistry and biology to DMPK, developability, process development, […]
Read more

2026.03.27

Sai Life Sciences hosts Biotech Pitch Day 2026 at Boston Site

Sai Life Sciences successfully hosted its Biotech Pitch Day 2026 at its Boston-area site on March 19, bringing together a dynamic group of emerging biotech innovators, scientific leaders, and industry experts. The event was designed as a platform for early-stage biotech companies to showcase their science, strengthen visibility, and engage with potential collaborators across the […]
Read more